Sort
4,870 grants matching “glp 1”
Novel Adjunctive Therapies for NeuroAIDS
$1,291,068Harris A Gelbard · University Of Rochester · P01 · FY2013 · MH
Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD
$1,290,570James G. Moe · Oligomerix, Inc · R44 · FY2021 · AG
Novel Adjunctive Therapies for NeuroAIDS
$1,290,412Harris A Gelbard · University Of Rochester · P01 · FY2011 · MH
Heart Muscle Regeneration
$1,290,338Bhawanjit K Brar · Jaan Biotherapeutics, Inc. · R44 · FY2025 · HL
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
$1,284,815Khalil N Bitar · Cellf-Bio Inc · R44 · FY2018 · DK
Novel Therapeutic Agents to Reverse Opioid Overdose
$1,283,728Xinhua Li · Clear Scientific, Llc · R44 · FY2021 · DA
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels
$1,283,183Fernando Aleman Guillen · Navega Therapeutics, Inc. · R44 · FY2022 · CA
SBIR Phase II: Development of Injectable, Enzyme-Degradable Poly(carboxybetaine) Hydrogel Formulations as Aesthetic and Surgical Tissue Fillers
$1,282,979Andrew Sinclair · Taproot Medical Technologies · · FY2019 · TIP
Novel Cannabinoid Receptor Modulators
$1,281,514Malliga Iyer · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2023 · AA
PTE-based drug for antibiotic-resistant anthrax
$1,280,271Protez Pharmaceuticals, Inc. · U01 · FY2004 · AI
A Resource for Biomedical Mass Spectrometry
$1,280,114Michael L Gross · Washington University · P41 · FY2009 · RR
Preclinical and Clinical Evaluation of Humanized NM9405
$1,277,607Rekha Bansal · Novelmed Therapeutics, Inc. · R44 · FY2017 · HL
Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
$1,276,514Jaipal Singh · Vasculonics, Llc · R44 · FY2025 · HL
Animal Medicine COVID Support
$1,272,902Ruth Woodward · National Institute Of Allergy And Infectious Diseases · ZIG · FY2022 · AI
Glial Progenitor Cells for Treatment of ALS
$1,270,188Linda L Kelley · University Of Utah · U01 · FY2009 · NS
Glial Progenitor Cells for Treatment of ALS
$1,270,188Linda L Kelley · University Of Utah · U01 · FY2009 · NS
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
$1,268,438Mone Zaidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · AG
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
$1,267,500Mone Zaidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · AG
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
$1,267,500Mone Zaidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · AG
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
$1,267,500Mone Zaidi · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AG
Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD
$1,266,814Michael Kyba · Myogenica Inc. · R42 · FY2025 · AR
Development of a universal gene therapy for hemophilia A or B with or without inhibitors
$1,266,694Paris Margaritis · Geneventiv Therapeutics, Inc. · R44 · FY2025 · HL
SuperGAGs for Intravesicular Treatment of Interstitial Cystitis
$1,266,580Robert Evan Hurst · Glycologix, Llc · R44 · FY2021 · DK
Pulmonary Valved Graft with Regeneration Potential for Pediatric Patients
$1,265,524Ajay Houde · Annoviant, Inc · R44 · FY2025 · HL
A Pan-Dengue Virus Immunotherapeutic for Prevention and Treatment
$1,262,889Leslie S Johnson · Macrogenics, Inc. · R01 · FY2012 · AI